Cardiac Resynchronization Therapy and Hypertrophic Cardiomyopathy: A Comprehensive Review

Related Experiment Video

Updated: Aug 9, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Andrei Dan Radu1,2, Cosmin Cojocaru1,2, Sebastian Onciul1,2

  • 1Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Biomedicines
|February 25, 2023
PubMed

Insights

Cardiac resynchronization therapy (CRT) may benefit hypertrophic cardiomyopathy (HCM) patients with heart failure and prolonged QRS duration. Studies suggest CRT can improve symptoms, exercise capacity, and left ventricular function in specific HCM patient groups.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is an inherited heart muscle disease causing left ventricle (LV) hypertrophy and potential outflow tract obstruction.
  • Patients with HCM may develop heart failure (HF) with reduced ejection fraction or left bundle branch block (LBBB), particularly with disease progression or after myectomy.
  • Cardiac resynchronization therapy (CRT) is a treatment for heart failure patients with specific electrical conduction abnormalities.

Purpose of the Study:

  • To review and reassess the role and importance of CRT in managing patients with hypertrophic cardiomyopathy.
  • To contextualize current research on CRT efficacy in diverse HCM patient populations.
  • To identify potential patient selection criteria for CRT in HCM.

Main Methods:

  • Systematic review and analysis of existing studies on CRT in HCM patients.
  • Comparison of outcomes in HCM patients with LBBB or reduced LVEF undergoing CRT.
  • Evaluation of electrical and imaging parameters for patient stratification.

Main Results:

  • CRT may improve symptoms, exercise capacity, and LV ejection fraction (LVEF) in HCM patients with myectomy-induced LBBB.
  • CRT can enhance NYHA class, LV systolic performance, and promote reverse remodeling in end-stage/dilated HCM with prolonged QRS.
  • Further research is needed due to limited current data.

Conclusions:

  • CRT shows potential benefits for specific subgroups of HCM patients, including those with LBBB or advanced HF.
  • Careful patient selection using electrical and imaging markers is crucial for optimizing CRT outcomes in HCM.
  • More extensive clinical trials are required to establish definitive guidelines for CRT use in HCM.

Keywords:
apical rockingcardiac resynchronization therapyend-stage/dilated hypertrophic cardiomyopathyhypertrophic cardiomyopathyleft bundle branch block

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

799

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
22
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
21
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
15
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
15
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
27
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
21